ARTICLE | Clinical News
Reslizumab regulatory update
September 28, 2015 7:00 AM UTC
FDA’s Pulmonary-Allergy Drugs Advisory Committee will meet on Dec. 9 to discuss a BLA for IV reslizumab from Teva to reduce exacerbations, relieve symptoms and improve lung function in patients ages >...